Recent News

​

September 19, 2024 — Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting  Read more.

​

September 11, 2024 — Neuraptive Therapeutics Inc. Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair Read more.

 

February 22, 2024 — Neuraptive Therapeutics Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data Read more.

​

January 15, 2024 — Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset Read more.

​

January 8, 2024 — Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves Read more.

​

February 27, 2023 — Neuraptive Therapeutics, Inc. Strengthens its Board of Directors With Appointment of Cary Sucoff, J.D. Read more.

​

November 17, 2022 — Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board. Read more.

​

October 24, 2022 — Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair. Read more.

​

July 21, 2022 — Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma. Read more.

​

April 13, 2021 — Neuraptive Therapeutics Announces FDA Clearance of a Second IND Application for NTX-001 in the Prevention of Postoperative Facial Paralysis and Plans to Initiate a Phase 2 Clinical Study Later This Year. Read more. 

​

October 20, 2020 — Neuraptive Therapeutics Announces Activation of First Clinical Site in Phase 2 Study of NTX-001 for the Treatment of Nerve Repair and the Appointment of Industry Veteran David Pierce to Board of Directors. Read more. 

​

June 23, 2020 — Neuraptive Therapeutics Appoints Robert S. Radie as Chief Executive Officer and Chairman of the Board. Read more. 

May 14, 2020 — Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program for Treatment of Patients with Peripheral Nerve Injuries. Read more.

​

April 28, 2020 — Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries. Read more.

​

June 11, 2019 — Neuraptive Therapeutics Announces Evan Tzanis as Executive Vice President, Head of R&D. Read more.

​

December 19, 2018Neuraptive Therapeutics, Inc., a biotech startup based in Colorado and Pennsylvania, raised $11.5 million in a Series A funding round led by New Rhein Healthcare Investors LLC. — Read more.